01:49 PM EST, 03/08/2024 (MT Newswires) -- Health care stocks were lower Friday afternoon, with the NYSE Health Care Index decreasing 0.2% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%.

The iShares Biotechnology ETF (IBB) eased 0.1%.

In corporate news, Eli Lilly ( LLY ) shares fell 3% after the company said the US Food and Drug Administration will call an advisory committee meeting to discuss the phase 3 trial of donanemab in early symptomatic Alzheimer's disease.

Novo Nordisk ( NVO ) plans to offer the pill version of its experimental weight loss drug amycretin this decade, Reuters reported Friday, citing Martin Holst Lange, the company's head of development. Novo Nordisk ( NVO ) shares were falling 3%.

Amylyx Pharmaceuticals ( AMLX ) plunged 82% after saying its phase 3 trial assessing AMX0035 in people with amyotrophic lateral sclerosis failed to meet the primary and secondary endpoints.